Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Alzheimer & Dementia Related Cognitive Disorders Topic Center

Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
An elderly woman sits on a couch
News
Increasing Depression Symptoms in Older Adults Associated With Amyloid Accumulation
09/09/2024
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
an older adult lies in a hospital bed with head turned looking out of a window
News
Suvorexant Associated With Lower Delirium Rates in Some Hospitalized Older Adults
08/29/2024
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting...
08/29/2024
Psych Congress Network
Collaborative Dementia Care Tied with Improved Outcomes
News
Collaborative Dementia Care Tied With Improved Outcomes
08/14/2024
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care...
08/14/2024
Neurology
From Neurology
marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
The US Food and Drug Administration headquarters sign.
FDA Approves Donanemab for Early Alzheimer Disease Treatment
07/02/2024
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug...
07/02/2024
Psych Congress Network
Alzheimer and cognitive decline graphic
News
Novel AD Treatment Approach Shows Promise in First Human Trial
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network
Lecanemab AD Treatment Could Have Low Eligibility
News
Lecanemab AD Treatment Could Have Low Eligibility Rate
06/19/2024
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently...
06/19/2024
Neurology
From Neurology
Sleep apnea during REM cycle
News
Obstructive Sleep Apnea Events During REM Sleep Impacts Verbal Memory in Those at Risk for AD
05/20/2024
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive...
05/20/2024
Neurology
From Neurology
Genetic Variant Appears to Protect Against Alzheimer Disease in At-Risk Individuals
News
Genetic Variant Appears to Protect Against Alzheimer Disease in At-Risk Individuals
04/29/2024
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease...
04/29/2024
Neurology
From Neurology

Quizzes

quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
Why do hurricanes increase mortality risk in ADRD populations?
Quiz
Why do hurricanes increase mortality risk in ADRD populations?
04/04/2023
Do you remember this study?
Do you remember this study?
Do you remember this study?
04/04/2023
Psych Congress Network
Four pencils with their erasers spelling out "quiz."
Quiz
What strategies can individuals use to reduce their risk of Alzheimer disease?
09/28/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
09/28/2022
Psych Congress Network
quiz
Quiz
What role does norepinephrine play in bipolar disorder symptom presentation?
08/07/2024
In bipolar disorder, how do norepinephrine (also referred to as noradrenaline) levels impact episodes of mania? Take the quiz!
In bipolar disorder, how do norepinephrine (also referred to as noradrenaline) levels impact episodes of mania? Take the quiz!
In bipolar disorder, how do...
08/07/2024
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
Expert Insights Quiz
HIPPA Considerations for Social Media
07/22/2024
Hone your telehealth practice and knowledge with this quiz!
Hone your telehealth practice and knowledge with this quiz!
Hone your telehealth practice...
07/22/2024
Psych Congress Network
How many symptoms must be present in order to diagnose adult ADHD?
Quiz
How many symptoms must be present in order to diagnose adult ADHD?
07/17/2024
Challenge your diagnostic knowledge!
Challenge your diagnostic knowledge!
Challenge your diagnostic...
07/17/2024
Psych Congress Network
How easy is it to switch patients from olanzapine to olanzapine samidorphan?
Quiz
How easy is it to switch patients from olanzapine to olanzapine samidorphan?
07/16/2024
Do you remember this insight from Dr Jain?
Do you remember this insight from Dr Jain?
Do you remember this insight...
07/16/2024
Psych Congress Network
quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
A cartoon illustration of a brain with two medical professionals standing on either side; one holds up a magnifying glass to the brain
Quiz
Differences in ADHD Symptoms Due to Sex
07/02/2024
Do you know what the DSM-5-TR says on this topic? Find out with this quiz!
Do you know what the DSM-5-TR says on this topic? Find out with this quiz!
Do you know what the DSM-5-TR...
07/02/2024
Psych Congress Network
quiz
Quiz
Which factor is NOT consideration when choosing an antidepressant medication?
06/28/2024
Which factor is NOT a consideration when choosing an antidepressant medication according to the APA's major depressive disorder practice guidelines? Take the quiz to find out!
Which factor is NOT a consideration when choosing an antidepressant medication according to the APA's major depressive disorder practice guidelines? Take the quiz to find out!
Which factor is NOT a...
06/28/2024
Psych Congress Network
quiz
Quiz
Which symptoms of schizophrenia must be present to make a diagnosis?
06/21/2024
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Two of the 5 characteristic...
06/21/2024
Psych Congress Network
an illustrated head in profile with brain, against a pink background.
Quiz
DSM-5-TR: Opioid-Induced Mental Disorders
06/18/2024
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the...
06/18/2024
Psych Congress Network
Can stimulant use increase risk of heart damage in young adults with ADHD?
Quiz
Can stimulant use increase risk of heart damage in young adults with ADHD?
06/17/2024
Time for a pop quiz!
Time for a pop quiz!
Time for a pop quiz!
06/17/2024
Psych Congress Network

Insights

marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Leslie Citrome, MD, MPH.
Videos
Addressing Agitation in Dementia
11/09/2023
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals...
11/09/2023
Psychiatry & Behavioral Health
Dr Paul Schulz
Videos
Lecanemab Considerations and Efficacy
10/16/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
10/16/2023
Psych Congress Network
Dr Paul Schulz
Videos
Patient Considerations When Prescribing Lecanemab for Alzheimer Disease
09/22/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
09/22/2023
Psych Congress Network
Dr Paul Schulz
Videos
Advantages and Drawbacks of Lecanemab in Alzheimer Disease Treatment
09/11/2023
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the...
09/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
Telepsychiatry Practice for Geriatric Patients
08/11/2023
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych...
08/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
What the Data Tells Us About Telepsychiatry Efficacy and Popularity
07/20/2023
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric...
07/20/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Douglas_Scharre_alzheimers_aducanumab
Videos
Putting Research Into Practice With Aducanumab for Alzheimer Disease
08/27/2021
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre,...
08/27/2021
Psych Congress Network
Improving Cognition in Patients With Alzheimer’s Disease
Videos
Improving Cognition in Patients With Alzheimer’s Disease
11/11/2020
In this video, geriatric psychiatrist Marc E. Agronin, MD, discusses medications that may improve cognition in patients with Alzheimer's disease.
In this video, geriatric psychiatrist Marc E. Agronin, MD, discusses medications that may improve cognition in patients with Alzheimer's disease.
In this video, geriatric...
11/11/2020
Psych Congress Network
Nishi Bhopal, MD
Q&As
Dispelling Common Misconceptions About Sleep Medicine
08/08/2024
Nishi Bhopal, MD, clarifies 5 common misconceptions about sleep medicine for mental health care practice.
Nishi Bhopal, MD, clarifies 5 common misconceptions about sleep medicine for mental health care practice.
Nishi Bhopal, MD, clarifies 5...
08/08/2024
Psych Congress Network
Julie Carbray, PhD, APRN
Videos
Can ADHD be properly evaluated and treated via telehealth?
08/06/2024
In this video, Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, offers practical guidance for telehealth providers screening for, diagnosing, and treating attention-deficit/hyperactivity disorder (ADHD) in pediatric and/or adult patients. 
In this video, Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, offers practical guidance for telehealth providers screening for, diagnosing, and treating attention-deficit/hyperactivity disorder (ADHD) in pediatric and/or adult patients. 
In this video, Julie Carbray,...
08/06/2024
Psych Congress Network
Julie Carbray, PhD
Videos
Unraveling the Diagnosis: Differentiating Between ADHD and Bipolar Disorder
08/06/2024
Join Julie Carbray, PhD, APRN, clinical professor of psychiatry and nursing at the University of Illinois Chicago, as she delves into the best practices for diagnosing attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder.
Join Julie Carbray, PhD, APRN, clinical professor of psychiatry and nursing at the University of Illinois Chicago, as she delves into the best practices for diagnosing attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder.
Join Julie Carbray, PhD, APRN,...
08/06/2024
Psych Congress Network
Julie Carbray, PhD
Videos
Updates in Bipolar Disorder Treatment
07/31/2024
Join Dr Julie Carbray as she delves into the recent advancements and emerging therapies in bipolar disorder treatment.
Join Dr Julie Carbray as she delves into the recent advancements and emerging therapies in bipolar disorder treatment.
Join Dr Julie Carbray as she...
07/31/2024
Psych Congress Network
marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Drs Podesta and Carbray
Podcasts
Managing Comorbid Bipolar Disorder & SUD: Treatment and Communication
07/22/2024
Drs Podesta and Carbray examine available treatments, recommended strategies, and how clinicians can better communicate with patients with this comorbidity.
Drs Podesta and Carbray examine available treatments, recommended strategies, and how clinicians can better communicate with patients with this comorbidity.
Drs Podesta and Carbray examine...
07/22/2024
Psych Congress Network
Nishi Bhopal, MD
Q&As
The Importance of Sleep Education for Mental Health Clinicians
07/16/2024
Nishi Bhopal, MD, discusses how mental health clinicians can more closely incorporate sleep disorder screening, diagnosis, and treatment into their practices.
Nishi Bhopal, MD, discusses how mental health clinicians can more closely incorporate sleep disorder screening, diagnosis, and treatment into their practices.
Nishi Bhopal, MD, discusses how...
07/16/2024
Psych Congress Network
Amber Hoberg, MSN, APRN, PMHNP-BC
Videos
Comparing VMAT-2 Inhibitor Options for Tardive Dyskinesia Treatment
07/15/2024
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN,...
07/15/2024
Psych Congress Network
Amber Hoberg, MSN, APRN, PMHNP-BC
Videos
Comparing VMAT-2 Inhibitor Options for Tardive Dyskinesia Treatment
07/15/2024
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN,...
07/15/2024
Psych Congress Network

Practice Tools

Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
An elderly woman sits on a couch
News
Increasing Depression Symptoms in Older Adults Associated With Amyloid Accumulation
09/09/2024
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
an older adult lies in a hospital bed with head turned looking out of a window
News
Suvorexant Associated With Lower Delirium Rates in Some Hospitalized Older Adults
08/29/2024
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting...
08/29/2024
Psych Congress Network
Collaborative Dementia Care Tied with Improved Outcomes
News
Collaborative Dementia Care Tied With Improved Outcomes
08/14/2024
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care...
08/14/2024
Neurology
marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
The US Food and Drug Administration headquarters sign.
FDA Approves Donanemab for Early Alzheimer Disease Treatment
07/02/2024
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug...
07/02/2024
Psych Congress Network
Alzheimer and cognitive decline graphic
News
Novel AD Treatment Approach Shows Promise in First Human Trial
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network
Lecanemab AD Treatment Could Have Low Eligibility
News
Lecanemab AD Treatment Could Have Low Eligibility Rate
06/19/2024
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently...
06/19/2024
Neurology
Sleep apnea during REM cycle
News
Obstructive Sleep Apnea Events During REM Sleep Impacts Verbal Memory in Those at Risk for AD
05/20/2024
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive...
05/20/2024
Neurology
a caregiver speaks with a doctor
News
Caregivers Confirm Usability of Schizophrenia Cognition Rating Scale
11/14/2024
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving...
11/14/2024
Psych Congress Network
An illustrated picture shows two cartoon doctors, one holding up a magnifying glass to a cartoon brain.
Conference Coverage
Flexible Dosing of Esketamine Nasal Spray Effective Over Long-Term
11/12/2024
Analysis of a long-term extension study of flexibly dosed esketamine nasal spray, in combination with an oral antidepressant, found durable long-term efficacy and safety of the treatment whether dosed weekly, every other week, or every 4...
Analysis of a long-term extension study of flexibly dosed esketamine nasal spray, in combination with an oral antidepressant, found durable long-term efficacy and safety of the treatment whether dosed weekly, every other week, or every 4...
Analysis of a long-term...
11/12/2024
Psychiatry & Behavioral Health
Jonathan Meyer, MD
Videos
Unpacking Negative Symptoms, Medication Adverse Effects, and Emerging Schizophrenia Treatments
11/11/2024
Jonathan Meyer, MD, offers his clinical insights on schizophrenia management.
Jonathan Meyer, MD, offers his clinical insights on schizophrenia management.
Jonathan Meyer, MD, offers his...
11/11/2024
Psych Congress Network
Thomas L. Schwartz, MD
Q&As
How Psychiatrists Can Address Sleep-Wake Disorders Effectively
11/09/2024
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares...
11/09/2024
Psychiatry & Behavioral Health
Stephen M. Stahl
Conference Coverage
At the NEI Fall Congress, Leading Faculty Reflect on the Evolution of Psychiatry and What the Future May Hold
11/08/2024
The 2024 Neuroscience Education Institute (NEI) Fall Congress commenced with opening remarks from Andrew J. Cutler, MD, Chairman, and the highly anticipated keynote address from Stephen M. Stahl, MD, PhD, DSc (Hon.), Chairman Emeritus.
The 2024 Neuroscience Education Institute (NEI) Fall Congress commenced with opening remarks from Andrew J. Cutler, MD, Chairman, and the highly anticipated keynote address from Stephen M. Stahl, MD, PhD, DSc (Hon.), Chairman Emeritus.
The 2024 Neuroscience Education...
11/08/2024
Psychiatry & Behavioral Health
Desiree Matthews
Schizophrenia Conference Insights
New Class of Medication Offers Innovative Treatment for Schizophrenia Symptoms
11/07/2024
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights...
11/07/2024
Psych Congress Network
NEI Fall Congress 2024
Conference Coverage
Medication Management, Care Enhancements Under the Spotlight at the 20th Annual NEI Fall Congress
11/07/2024
The 20th annual NEI Fall Congress provides a space—both in person and online—where leading minds in psychiatry share current and emerging treatment strategies with the next generation of mental health care professionals.
The 20th annual NEI Fall Congress provides a space—both in person and online—where leading minds in psychiatry share current and emerging treatment strategies with the next generation of mental health care professionals.
The 20th annual NEI Fall...
11/07/2024
Psychiatry & Behavioral Health
Adults Who Smoke Have More Chronic Pain, Use More Opioids
News
Adults Who Smoke Have More Chronic Pain, Use More Opioids
11/07/2024
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain,...
11/07/2024
Psych Congress Network
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network

News Articles

Alzheimer and cognitive decline graphic
News
Novel AD Treatment Approach Shows Promise in First Human Trial
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network
Lecanemab AD Treatment Could Have Low Eligibility
News
Lecanemab AD Treatment Could Have Low Eligibility Rate
06/19/2024
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently...
06/19/2024
Neurology
Sleep apnea during REM cycle
News
Obstructive Sleep Apnea Events During REM Sleep Impacts Verbal Memory in Those at Risk for AD
05/20/2024
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive...
05/20/2024
Neurology
Genetic Variant Appears to Protect Against Alzheimer Disease in At-Risk Individuals
News
Genetic Variant Appears to Protect Against Alzheimer Disease in At-Risk Individuals
04/29/2024
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease...
04/29/2024
Neurology
Illustration of the brain
News
Antipsychotics for Dementia Associated With More Adverse Outcomes Than Previously Thought
04/22/2024
Antipsychotic use in patients with dementia is associated with an increased risk for a handful of serious adverse outcomes, including pneumonia, acute kidney injury, venous thromboembolism, and stroke.
Antipsychotic use in patients with dementia is associated with an increased risk for a handful of serious adverse outcomes, including pneumonia, acute kidney injury, venous thromboembolism, and stroke.
Antipsychotic use in patients...
04/22/2024
Psych Congress Network
Doctors examine brain scans
News
Rate of Frontotemporal Dementia in Patients With ALS Higher Than Previous Estimates
03/04/2024
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients...
03/04/2024
Neurology
Brain scan
News
Study Reveals Structural Brain Subgroups in Aging, Key for Early Disease Detection
03/01/2024
Recent study reveals significant insights into the structural brain changes associated with aging in individuals without diagnosed cognitive impairment.
Recent study reveals significant insights into the structural brain changes associated with aging in individuals without diagnosed cognitive impairment.
Recent study reveals significant...
03/01/2024
Psych Congress Network
A doctor examines MRI scans of a brain.
News
Low-Dose IL-2 Shows Potential for Alzheimer Disease, Phase 2a Trial Underway
02/07/2024
After promising findings in a small, open-label, phase 1 pilot study of low-dose interleukine-2 (IL-2) immunotherapy in patients with Alzheimer disease (AD), researchers are proceeding with a double-blinded, randomized, placebo-controlled,...
After promising findings in a small, open-label, phase 1 pilot study of low-dose interleukine-2 (IL-2) immunotherapy in patients with Alzheimer disease (AD), researchers are proceeding with a double-blinded, randomized, placebo-controlled,...
After promising findings in a...
02/07/2024
Neurology
Hearing Loss Prevention Could Delay, Prevent Dementia Onset
News
Hearing Loss Prevention Could Delay, Prevent Dementia Onset
01/29/2024
Hearing aids could delay or prevent dementia onset, according to a population-based cohort study recently published in the journal JAMA Otolaryngology Head & Neck Surgery.
Hearing aids could delay or prevent dementia onset, according to a population-based cohort study recently published in the journal JAMA Otolaryngology Head & Neck Surgery.
Hearing aids could delay or...
01/29/2024
Psych Congress Network
Excessive TV Use Could Raise Risk of Dementia, PD, and Depression
News
Excessive TV Use Could Raise Risk of Dementia, PD, and Depression
01/15/2024
Excessive TV watching was associated with an increased risk of dementia, Parkinson disease (PD), and depression, according to recent study results.
Excessive TV watching was associated with an increased risk of dementia, Parkinson disease (PD), and depression, according to recent study results.
Excessive TV watching was...
01/15/2024
Neurology
A health care professional reviews paperwork while sitting at a desk in front of a computer
News
Added Remote Support for Antidepressant Discontinuation Offers Only Small Benefits
08/07/2024
Adding internet and phone support to a family practitioner review for possible discontinuation of long-term antidepressants provided small additional benefits.
Adding internet and phone support to a family practitioner review for possible discontinuation of long-term antidepressants provided small additional benefits.
Adding internet and phone...
08/07/2024
Psych Congress Network
Meta-Analysis Characterizes Neural Activation Differences in ADHD and ASD
News
Meta-Analysis Characterizes Neural Activation Differences in ADHD and ASD
08/05/2024
A meta-analysis of 243 studies found both similar and different neural activations during task completion in participants with ADHD and ASD compared with typically developing control subjects. Researchers published their findings in the...
A meta-analysis of 243 studies found both similar and different neural activations during task completion in participants with ADHD and ASD compared with typically developing control subjects. Researchers published their findings in the...
A meta-analysis of 243 studies...
08/05/2024
Psych Congress Network
nursing home care
News
CYP2D6-Metabolized Opioids and Antidepressant Concomitant Use Increases Adverse Events in Nursing Home Residents
08/02/2024
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light...
08/02/2024
Psych Congress Network
A brain puzzle against an orange background
News
Most Patients With Schizophrenia Relapse-Free With Paliperidone Palmitate, Open Label Extension Study Finds
08/01/2024
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension...
08/01/2024
Psych Congress Network
Doctor and patient
News
Clinician-Level Differences Significantly Affect MDD Prescribing, Outcomes
08/01/2024
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing...
08/01/2024
Psych Congress Network
Continuing ADHD Treatment During Pregnancy May Help Patients Better Manage OUD
News
Continuing ADHD Treatment During Pregnancy May Help Patients Better Manage OUD
07/31/2024
Pregnant patients with comorbid ADHD and OUD who remain on their ADHD medications throughout pregnancy are more likely to adhere to OUD treatment and less likely to overdose than patients who stop taking ADHD medication, according to results...
Pregnant patients with comorbid ADHD and OUD who remain on their ADHD medications throughout pregnancy are more likely to adhere to OUD treatment and less likely to overdose than patients who stop taking ADHD medication, according to results...
Pregnant patients with comorbid...
07/31/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
07/24/2024
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
News
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
07/24/2024
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug...
07/24/2024
Psych Congress Network
FDA building sign
News
FDA Declines to Approve OX124 Nasal Spray for Opioid Overdose Treatment
07/23/2024
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug...
07/23/2024
Psych Congress Network
One in 7 Patients Experience Antidepressant Discontinuation Symptoms, Study Says
News
One in 7 Patients Experience Antidepressant Discontinuation Symptoms, Study Says
07/22/2024
Including non-specific effects, approximately 15% or 1 in 6 to 7 patients experience antidepressant discontinuation symptoms, according to recent systematic review and meta-analysis results published in The Lancet Psychiatry. 
Including non-specific effects, approximately 15% or 1 in 6 to 7 patients experience antidepressant discontinuation symptoms, according to recent systematic review and meta-analysis results published in The Lancet Psychiatry. 
Including non-specific effects,...
07/22/2024
Psych Congress Network

Posters

Utilization of Psychiatric Pharmacogenomic Testing by Primary Care Physicians and Advanced Practice Providers: Confidence and Implementation Barriers
Routine implementation of pharmacogenomic testing for mental health and other conditions treated in primary care may require overcoming barriers such as cost to the patient and knowledge ...
10/26/2023
Valbenazine Improves Tardive Dyskinesia With or Without Concomitant Antipsychotic Therapy: A Meta-Analysis of Three Long-Term Valbenazine Trials
Valbenazine is indicated for once-daily treatment of tardive dyskinesia (TD), a movement disorder associated with prolonged antipsychotic exposure. Data from 3 long-term studies (KINECT™-...
10/26/2023
Veterans’ Intensive​ PCMHI Boot Camp​ (VIP Boot Camp)
Veterans Intensive Primary Care Mental Health Integration Bootcamp (VIP Bootcamp): An upstream solution to Mental Health(MH) access issues within the VA system
10/26/2023
Viloxazine ER (Qelbree®) Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Topline Results of a Phase IV Safety Trial
Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...
10/26/2023
Withdrawal Catatonia: A Rare Case of Treatment-Resistant Catatonia Secondary to Quetiapine Withdrawal
Catatonia is a psychomotor syndrome with well-defined clinical characteristics, although the neurological mechanisms involved remain unknown. In this study, we report a case of a patient ...
10/26/2023
Zuranolone Safety and Tolerability in Adults with Postpartum Depression: Analyses from SKYLARK, a 50 mg Placebo-Controlled Study
In the SKYLARK Study, zuranolone 50 mg was generally well tolerated in adults with postpartum depression; treatment-emergent adverse events (TEAEs) led to zuranolone dose reduction and di...
10/26/2023
Using Chess as a Novel Means to Cure Treatment Refractory Catatonia
The subject matter of the poster includes a case report of a patient with treatment refractory catatonia whose condition rapidly improved following a game of chess, one of the patient's k...
10/26/2023
Understanding the Real-World Prescription Patterns and Impact of Atypical Antipsychotic Augmentation Timing on Healthcare Cost in Adult Major Depressive Disorder in the United States: A Systematic Literature Review
This study examined the utilization pattern of augmentation with atypical antipsychotics after partial or no response to antidepressants in patients with MDD. The antidepressant prescript...
10/26/2023
Unique Features of the Rapid Mood Screener Enable Detection of Bipolar I Disorder in a Primary Care Practice
The Rapid Mood Screener (RMS) is a self-administered screening tool to help differentiate bipolar I disorder from major depressive disorder. Cases were identified from a primary care sett...
10/26/2023
Use Of VMAT2 Inhibitors For Tardive Dyskinesia In Geriatric Populations - A Case Study
This case report discusses the safety and efficacy of VMAT2 inhibitors in treating antipsychotic induced tardive dyskinesia in adults >55 years old. It also highlights the increased ri...
10/26/2023

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement